Respiratory Infections and Inflammations with MCC DRG Reimbursement

Summary & Overview

Respiratory Infections and Inflammations with MCC: Inpatient Reimbursement Overview

DRG 177 addresses inpatient respiratory infections and inflammations when a Major Complication or Comorbidity is coded, capturing cases with greater clinical severity and resource needs. This matters for inpatient reimbursement because the presence of a Major Complication or Comorbidity increases the Diagnosis-Related Group weight and thus Medicare payment relative to less severe respiratory infection classifications.

Respiratory Infections and Inflammations with MCCDRG Respiratory Infections and Inflammations with MCCDRG 177Diagnosis-Related GroupInpatient ReimbursementMedicarePulmonologyInfectious DiseaseCritical Care

DRG 177 Overview

DRG 177 covers hospital inpatient cases for respiratory infections and inflammations when a Major Complication or Comorbidity is present, representing more severe presentations such as respiratory failure, severe sepsis, or other significant systemic effects. This Diagnosis-Related Group groups patients with higher resource use and longer lengths of stay compared with lower-severity respiratory infection DRGs, which affects Medicare payment by assigning a higher relative weight for reimbursement. Accurate clinical documentation and coding of the Major Complication or Comorbidity are central to assignment to DRG 177, influencing claim payment and hospital revenue. Facilities should be aware that complications related to the respiratory condition drive the increased payment level.

National Payment Rates

Across commercial payers the observed payment range spans roughly from $1.1K to $67K, with the widest spread between Anthem (min/max up to $67K) and other payers. Blue Cross Blue Shield, Cigna, Aetna and Anthem show differing median levels, reflecting notable variability in negotiated rates across payers. See the table and chart below for payer-specific quartiles and distributions.

Mean Rates by Payer — National — DRG 177

The CMS 2023 data represent national Medicare FFS inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($16.1k), average submitted covered charges ($66.3k), average Medicare payment amount ($13.9k), and total discharges (168.969k).

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Payer rates for DRG 177 in Alaska span a wide range, with observed values from roughly $7.5K at the low end up to $67K at the high end across payers. Cigna’s median (~$37K) stands out as a notable positive deviation relative to national medians for comparable payers, while Blue Cross Blue Shield’s median of $24K sits nearer typical national levels. See the table and chart below for payer-specific quartiles and distributions.

Key Insights for Alaska

BCBS is the lowest paying payer for DRG 177 in Alaska with a median of $24K, while Cigna is the highest with a median of $37K.
Payer rates in Alaska range from approximately $7.5K to $67K across payers and percentiles, and Cigna’s higher median (~$37K) meaningfully exceeds national medians for major payers.

Clinical Trials

Acute therapeutic intervention trials evaluating novel or repurposed pharmacologic or biologic agents for severe respiratory infections in hospitalized adults with major complications (eg, respiratory failure, sepsis, or need for mechanical ventilation). These studies typically enroll patients early in their admission who meet criteria for a high-risk phenotype (advanced age, immunosuppression, significant comorbid cardiopulmonary disease) to assess endpoints such as time to clinical stabilization, need for ICU escalation, ventilator-free days, and in-hospital mortality. Results are directly relevant to inpatient care pathways and resource allocation for payers because they inform which acute treatments reduce length of stay, ICU utilization, and complication-related costs in DRG 177 patients.
Comparative effectiveness and antimicrobial stewardship studies comparing diagnostic-driven strategies (rapid pathogen identification, procalcitonin-guided therapy) versus standard empiric antibiotic approaches for complicated respiratory infections and inflammations. These trials enroll hospitalized patients with suspected bacterial or mixed infections and major complications to determine if targeted therapy reduces antibiotic exposure, adverse drug events, readmission, and secondary infections such as C. difficile. For providers and payers, evidence from these trials supports protocols that can lower medication costs, antimicrobial resistance burden, and downstream utilization while maintaining clinical outcomes for high-risk DRG 177 cohorts.
Post-discharge outcomes and care-transition studies focused on reducing readmissions and long-term morbidity after a complicated respiratory infection hospitalization, including programs testing comprehensive discharge bundles (pulmonary rehabilitation referrals, home oxygen titration, telemonitoring, and coordinated follow-up). These pragmatic trials recruit survivors of severe in-hospital infections with MCCs and measure 30–90 day readmission rates, functional status, quality of life, and downstream health care spending. Payers and hospital administrators use this evidence to design discharge processes and post-acute services that decrease costly readmissions and improve value for patients classified under DRG 177.

Related Codes

181-RESPIRATORY-NEOPLASMS-WITH-CC

Respiratory Neoplasms with CC: Inpatient Reimbursement Overview

183-MAJOR-CHEST-TRAUMA-WITH-MCC

Major Chest Trauma with MCC: Inpatient Reimbursement Overview

203-BRONCHITIS-AND-ASTHMA-WITHOUT-CC-MCC

Bronchitis and Asthma without CC/MCC: Inpatient Reimbursement Overview

186-PLEURAL-EFFUSION-WITH-MCC

Pleural Effusion with MCC: Inpatient Reimbursement Overview

208-RESPIRATORY-SYSTEM-DIAGNOSIS-WITH-VENTILATOR-SUPPORT-96-HOURS

Respiratory System Diagnosis with Ventilator Support <=96 Hours: Inpatient Reimbursement Overview

189-PULMONARY-EDEMA-AND-RESPIRATORY-FAILURE

Pulmonary Edema and Respiratory Failure: Inpatient Reimbursement Overview

197-INTERSTITIAL-LUNG-DISEASE-WITH-CC

Interstitial Lung Disease with CC: Inpatient Reimbursement Overview

180-RESPIRATORY-NEOPLASMS-WITH-MCC

Respiratory Neoplasms with MCC: Inpatient Reimbursement Overview

167-OTHER-RESPIRATORY-SYSTEM-O-R-PROCEDURES-WITH-CC

Other Respiratory System O.R. Procedures with CC: Inpatient Reimbursement Overview

201-PNEUMOTHORAX-WITHOUT-CC-MCC

Pneumothorax without CC/MCC: Inpatient Reimbursement Overview

Showing 1–10 of 40

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$16K	$66K	$14K	170K

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Mean Rates by Payer — Alaska — DRG 177

Key Insights for Alaska

BCBS is the lowest paying payer for DRG 177 in Alaska with a median of $24K, while Cigna is the highest with a median of $37K.
Payer rates in Alaska range from approximately $7.5K to $67K across payers and percentiles, and Cigna’s higher median (~$37K) meaningfully exceeds national medians for major payers.

Clinical Trials

Acute therapeutic intervention trials evaluating novel or repurposed pharmacologic or biologic agents for severe respiratory infections in hospitalized adults with major complications (eg, respiratory failure, sepsis, or need for mechanical ventilation). These studies typically enroll patients early in their admission who meet criteria for a high-risk phenotype (advanced age, immunosuppression, significant comorbid cardiopulmonary disease) to assess endpoints such as time to clinical stabilization, need for ICU escalation, ventilator-free days, and in-hospital mortality. Results are directly relevant to inpatient care pathways and resource allocation for payers because they inform which acute treatments reduce length of stay, ICU utilization, and complication-related costs in DRG 177 patients.
Comparative effectiveness and antimicrobial stewardship studies comparing diagnostic-driven strategies (rapid pathogen identification, procalcitonin-guided therapy) versus standard empiric antibiotic approaches for complicated respiratory infections and inflammations. These trials enroll hospitalized patients with suspected bacterial or mixed infections and major complications to determine if targeted therapy reduces antibiotic exposure, adverse drug events, readmission, and secondary infections such as C. difficile. For providers and payers, evidence from these trials supports protocols that can lower medication costs, antimicrobial resistance burden, and downstream utilization while maintaining clinical outcomes for high-risk DRG 177 cohorts.
Post-discharge outcomes and care-transition studies focused on reducing readmissions and long-term morbidity after a complicated respiratory infection hospitalization, including programs testing comprehensive discharge bundles (pulmonary rehabilitation referrals, home oxygen titration, telemonitoring, and coordinated follow-up). These pragmatic trials recruit survivors of severe in-hospital infections with MCCs and measure 30–90 day readmission rates, functional status, quality of life, and downstream health care spending. Payers and hospital administrators use this evidence to design discharge processes and post-acute services that decrease costly readmissions and improve value for patients classified under DRG 177.